ABBV 257

Drug Profile

ABBV 257

Alternative Names: ABBV-257; Dual-variable domain immunoglobulins 1; DVD 1; DVD-Ig 1

Latest Information Update: 14 Mar 2016

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Antirheumatics; Immunoglobulins; Monoclonal antibodies
  • Mechanism of Action Interleukin-17 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis

Most Recent Events

  • 01 Feb 2016 AbbVie completes a phase I trial in Rheumatoid arthritis (Treatment-experienced) in Germany (SC) (NCT02531178)
  • 01 Jul 2015 Phase-I clinical trials in Rheumatoid arthritis (Treatment-experienced) in Germany (SC) (NCT02531178)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top